Free Trial

KBC Group NV Trims Position in Enovis Corporation (NYSE:ENOV)

Enovis logo with Medical background

KBC Group NV decreased its position in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 97.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,587 shares of the company's stock after selling 99,972 shares during the period. KBC Group NV's holdings in Enovis were worth $99,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. US Bancorp DE raised its position in Enovis by 3.4% during the 4th quarter. US Bancorp DE now owns 18,569 shares of the company's stock valued at $815,000 after purchasing an additional 607 shares in the last quarter. State of Michigan Retirement System raised its holdings in shares of Enovis by 10.0% in the fourth quarter. State of Michigan Retirement System now owns 13,202 shares of the company's stock valued at $579,000 after acquiring an additional 1,200 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Enovis by 7.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 645,789 shares of the company's stock worth $28,337,000 after acquiring an additional 44,970 shares during the period. Arizona State Retirement System grew its holdings in Enovis by 2.6% during the 4th quarter. Arizona State Retirement System now owns 16,208 shares of the company's stock worth $711,000 after acquiring an additional 414 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Enovis during the 4th quarter valued at about $16,407,000. Institutional investors own 98.45% of the company's stock.

Enovis Stock Down 5.3%

Shares of ENOV stock traded down $1.91 during mid-day trading on Friday, hitting $34.03. 992,363 shares of the stock traded hands, compared to its average volume of 900,674. The stock has a market cap of $1.94 billion, a P/E ratio of -2.44 and a beta of 1.70. The stock's fifty day moving average is $33.00 and its two-hundred day moving average is $37.75. Enovis Corporation has a 52-week low of $28.83 and a 52-week high of $49.83. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.55 and a quick ratio of 1.32.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. The company had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. During the same quarter in the previous year, the firm earned $0.50 EPS. Enovis's revenue was up 8.2% compared to the same quarter last year. Equities analysts predict that Enovis Corporation will post 2.79 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ENOV. JMP Securities dropped their price objective on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Evercore ISI reduced their price objective on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research note on Tuesday. Needham & Company LLC reduced their price objective on shares of Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Canaccord Genuity Group reduced their price objective on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $55.60.

Read Our Latest Stock Analysis on ENOV

Enovis Profile

(Free Report)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Featured Stories

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

Should You Invest $1,000 in Enovis Right Now?

Before you consider Enovis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.

While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines